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ABSTRACT
Background:Most studies examining psychotropic medication use on cognition in older persons with dementia
include measures of global cognitive function. The present study examined the relationship between different
types of psychotropic medication and specific cognitive functions in older people with dementia.
Methods: Two hundred and six institutionalized older adults with dementia (180 women, mean age 85 years)
were administered neuropsychological tests. Psychotropic medication use was extracted from their medical
status and categorized as: sedatives, antidepressants and antipsychotics.
Results: Analysis of covariance revealed that psychotropic consumers, and particularly those who used
antipsychotics, performed worse on neuropsychological tests of executive/attentional functioning than non-
consumers. There were no differences between consumers of other classes of psychotropic drugs and non-
consumers. The number of psychotropic drugs used was inversely related to executive/attentional functioning.
Conclusions: These findings show that in institutionalized older adults with dementia, specific impairment of
cognitive function, i.e. executive/attentional impairments, are associated with antipsychotic medication use.
Future longitudinal studies are recommended.
Key words: antipsychotic agents, antidepressant agents, hypnotics and sedatives, cognitive performance, cognitive disorders, nursing homes,
homes for the aged
Introduction
Psychotropic medications such as sedatives, anti-
psychotics and antidepressants are commonly
prescribed in the nursing home setting. More
specifically, studies indicate that between 47% and
59% of the residents are prescribed some type of
psychotropic medication (Ruths et al., 2001; Lakey
et al., 2006; Snowdon et al., 2006; Tucker and
Hosford, 2008). In a study in which almost 70%
of the residents were diagnosed with dementia,
almost 80% of the total sample was regularly
given psychotropic medication (Hosia-Randell and
Pitka¨la¨, 2005). In view of this frequent use of
psychotropic medication, possible adverse effects
are a matter of concern. For instance, in the
general population, consumption of psychotropic
medication may lead to impairments of memory,
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attention and executive functioning (Brooks and
Hoblyn, 2007). Results of studies examining the
relationship between psychotropic medication and
cognition in older community-dwelling adults,
however, have been mixed. Several studies show
worse cognitive performance in psychotropic
medications users, e.g. users of benzodiazepines
(Wadsworth et al., 2005; Bierman et al., 2007), or
improved cognition after cessation of treatment with
benzodiazepines (Curran et al., 2003; McAndrews
et al., 2003). On the other hand, positive effects of
psychotropic use on cognition have been reported
as well (Brooks and Hoblyn, 2007).
It has been suggested that presence of an
underlying dementia process that does not exhibit
apparent cognitive impairment during assessment
(i.e. preclinical dementia), often accompanied
by depression (Palmer et al., 2007), may play
a role in the relationship between psychotropic
use and cognition, i.e. memory, in older people
(Allard et al., 2003). Older community-dwelling
people with dementia who use psychotropic
medication show a more rapid global cognitive
deterioration, as measured by a dementia scale,
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compared to people with dementia who do not use
psychotropic medication (Scha¨ufele et al., 2002).
Studies examining the relationship between certain
subtypes of psychotropic medication (i.e. sedatives,
antidepressants and antipsychotics) and cognition
in older persons with dementia have found incon-
sistent results. Some studies show that Alzheimer’s
disease (AD) patients whowere given antipsychotics
showed the same rate of cognitive decline as those
who were not (Caballero et al., 2006; Livingston
et al., 2007). In contrast, other studies with AD
patients have revealed positive (De Deyn et al.,
2004) and negative effects (Kennedy et al., 2005)
on global measures of cognitive functioning after
treatment with antipsychotic medication. After
adjustment of depressive symptoms, antidepressant
use was associated with a reduced cognitive decline
(asmeasured by theMini-mental State Examination
(MMSE; Folstein et al., 1975) in older persons
with AD (Mossello et al., 2008). No studies have
looked at the relationship between sedatives and
cognition in older persons with dementia. Although
some studies focus on a specific cognitive function,
such as autobiographical memory (Harrison and
Therrien, 2007), most studies focus on global
cognitive functioning. The present study takes a
next step by examining whether certain subtypes
of psychotropic medication use are associated with
impairment in specific cognitive functions, e.g.
memory, executive/attentional function, and overall
cognition in institutionalized older people with
dementia.
Methods
Subjects
A sample of older persons with dementia was
recruited from 28 nursing homes and homes for
the elderly in the Netherlands. The present study
used baseline data from a non-pharmacological
intervention study in institutionalized older adults
with dementia for which approval was granted
by the local Medical Ethical Committee. This
intervention study offered a scheduled activity over
six weeks and therefore required commitment to
the study for a longer period of time. Some 668
older residents (distributed over the 28 homes) were
screened for possible inclusion in the intervention
study. Inclusion criteria for participation were: (i)
>70 years old; (ii) diagnosis of dementia or presence
of cognitive impairment reported in the medical
chart. Exclusion criteria included: (i) an MMSE
(Folstein et al., 1975) score of < 10 or> 24 (the
focus was on participants in a mild to moderately
advanced stage of dementia since they may still
be capable of performing the neuropsychological
Table 1. Distribution of participants over the 28
nursing homes and homes for the elderly
NUM B E R
O F H OM E S
PA RT I C I PA N T S
( P E R H OM E )
P S Y C H OT RO P I C
C O N S UM E R S
..........................................................................................................................................................
1 36 14
1 23 13
1 22 13
1 10 2
1 9 5
4 8 21
3 6 6
4 5 9
2 4 6
8 3 9
2 2 0
28 206 98
tests administered in the present study); and
(ii) presence of acute psychiatric disorders that
may preclude participation in cognitive assessment
(e.g. psychosis and delirium, and disturbances
of consciousness). A total of 462 residents were
excluded from participation in the intervention
study: 303 residents did not meet the inclusion
criteria; 131 residents refused to participate; and 28
declined because of other reasons (because either
the family or carer did not agree, or participants
could not perform the neuropsychological test
assessment due to reasons of illness, temporal
hospitalization, or sudden transfer to another place
of residence). Consequently, baseline data were
available for 206 residents. For distribution of
participants over the 28 nursing homes and homes
for the elderly see Table 1.
SUBTYPE OF DEMENTIA, EDUCATION, AND
COMORBIDITY
Subtype of dementia was extracted from the
medical status by the primary investigator (L.E.)
and combined with the data resulting from
the neuropsychological assessment. To establish
subtype of dementia, DSM-IV criteria were used
(American Psychiatric Association, 1994). Level of
education was determined on a seven-point scale
ranging from 1 (less than elementary school) to 7
(university) (Verhage, 1964). Comorbid conditions
were reported from notes in the medical chart
and classified into specific categories, including:
cardiovascular conditions, skin disorders, tumors,
gastrointestinal disease, locomotor disturbances,
neuro- and radiculopathy, renal disease, pneumonic
disease, and endocrine disorders.
288 L. H. P. Eggermont et al.
ASSESSMENT OF MOOD
In view of the close relationship between cognitive
function and mood (Steffens, 2008), symptoms of
depression and anxiety were determined by the
Geriatric Depression Scale (GDS; Kok et al., 1993),
and the Symptom Checklist (SCL; Arrindell and
Ettema, 1986), respectively.
Assessment of specific cognitive functions
To assess various aspects of cognitive functioning,
neuropsychological tests were administered by
trained research assistants who were blinded to
study design. The memory tests comprised “Face
and Picture Recognition” from the Rivermead
Behavioural Memory Test (RBMT), which is
considered a test for measuring everyday memory
problems (Wilson et al., 1987), and the “Eight
Words Test” (Lindeboom and Jonker, 1989). This
word learning test includes three conditions: direct
recall, delayed recall, and delayed recognition. This
episodic memory test is specifically designed for
persons with memory problems (Lindeboom and
Jonker, 1989).
The executive/attentional function tests com-
prised “Digit Span,” a subtest of the Wechsler
Memory Scale-Revised (WMS-R), frequently ad-
ministered in the clinical setting (Loewenstein et al.,
1995) to measure attention and working memory
(Wechsler, 1987), and “Category Fluency,” which
provides a measure of a participant’s ability
to retrieve familiar information from semantic
memory (Snijders and Verhage, 1983) and is widely
used in older persons with cognitive impairment
(Beinhoff et al., 2005) .
Classification of psychotropic medication
Use of psychotropic medication was extracted
from the medical chart at the same time as the
neuropsychological assessment by the primary
investigator (L.E.). The medical status provided
detailed information on subtypes of drugs, date of
prescription, and information of the pharmacist.
Psychotropics were classified into three major
classes (Brooks and Hoblyn, 2007): (i) anxiolyt-
ics/hypnotic/sedatives (including benzodiazepines
and non-benzodiazepine sleeping pills); (ii)
antidepressants (including tricyclic antidepressants
and selective serotonin reuptake inhibitors); and
(iii) antipsychotics (including neuroleptics and
atypical antipsychotics).
Statistical analysis
Characteristics of the psychotropic medication
consumers and non-consumers were compared by
means of χ2 tests, Mann-Whitney U tests, or
independent-samples t-tests. For data reduction
purposes, the separate variables of the neuropsy-
chological tests were transformed into z-scores
and combined to form three cognitive domains,
based on a principal components factor analysis.
Differences between characteristics of psychotropic
consumers and non-consumers were used as
covariates. Analyses of covariance (ANCOVA) were
conducted on the cognitive domains. Comparisons
were made between psychotropic consumers versus
non-consumers and between consumers of each
psychotropic class separately. In the separate
analyses of the specific classes of psychotropic
medication, only factors that differed significantly
between specific psychotropic consumers and non-
consumers were used as covariates. Effect sizes
were estimated using partial eta squared (ηp2),
and interpreted as: small (ηp2 ≈ 0.01), medium
(ηp2 ≈ 0.06), and large (ηp2 > 0.13), following
Cohen’s standard (Cohen, 1992). The relationships
between the number of classes of psychotropic
medications and the cognitive domains were
explored by means of Spearman’s correlations.
Level of significance was set at 0.05.
Results
Participant characteristics
Mean age of all participants was 85.22 years (range
74–99 years). The total group consisted of 180
female and 26 male participants. Mean MMSE
score was 17.1 (ranges 10–24). Almost half of the
participants were using psychotropic medication
(47.6% consumers: n= 98, versus 52.4% non-
consumers: n= 108). Details on psychotropic
medication use are presented in Table 2. There
were no differences between consumers and non-
consumers with respect to age, MMSE score,
gender, comorbidity and use of cholinesterase-
inhibitors (Table 3). Participants revealed diagnoses
in their medical status of AD (n= 68), vascular
dementia (VaD) (n= 31), a combination of AD and
VaD (n= 15), frontotemporal dementia (n= 2),
or dementia not otherwise specified (n= 90).
The different dementia subtypes were equally
distributed between psychotropic consumers and
non-consumers (Mann-Whitney U: z=−0.58,
p= 0.562). There was a significant difference
in the level of symptoms of depression and
anxiety between psychotropic consumers and non-
consumers, and psychotropic consumers showed
lower levels of education compared to non-
consumers (see Table 3).
Cognitive functioning
The separate neuropsychological test variables were
combined using factor analysis to form three
Psychotropic medication and cognition in dementia 289
Table 2. Number of psychotropic drugs of the entire
study sample
F R E QU E N C Y (% )
( N = 2 0 6 )
........................................................................................................................................................
Psychotropic medication
consumers
98 (47.6)
Anxiolytics/hypnotic/sedatives
consumers
61 (29.6)
Antipsychotics consumers 44 (21.4)
Antidepressants consumers 39 (18.9)
Consumers of a single
psychotropic drug class
61 (29.6)
Consumers of 2 psychotropic
drug classes
28 (13.6)
Consumers of 3 psychotropic
drug classes
9 (4.4)
domains: (i) a domain based on tests appealing
to executive/attentional functioning (EF/attention
domain); (ii) a domain formed by tests appealing
to memory (memory domain); and (iii) all the
test variables together (overall cognition). The
four neuropsychological test variables that formed
the EF/attention domain were the digit span
forward, digit span backward, category fluency,
and eight words test immediate recall (Cronbach’s
α = 0.55). The four neuropsychological variables
that formed the Memory domain were RBMT
face recognition, RBMT picture recognition, eight
words test delayed recall, and the eight words
test recognition (Cronbach’s α = 0.67). All the
neuropsychological test variables together formed
overall cognition (Cronbach’s α = 0.66).
Psychotropic medication consumers versus
non-consumers
Since level of education and symptoms of depres-
sion and anxiety differed significantly between
psychotropic medication consumers and non-
consumers, all three variables were used as
covariates. The ANCOVA revealed that consumers
of psychotropic medication showed a significantly
worse performance on the EF/attention domain
compared to non-consumers (F(1,197)= 4.79,
p= 0.030, ηp2 = 0.024). There were no significant
differences between thememory domain and overall
cognition domain between consumers and non-
consumers of psychotropic medication (F(1,197)=
0.59, p= 0.444, ηp2 = 0.003 and F(1,197)= 0.40,
p= 0.526, ηp2 = 0.002, respectively). See Table 4
for means and standard deviations of the separate
cognitive tests and domains.
Different classes of psychotropic medication
The ANCOVA correcting for age and symptoms of
depression, revealed no differences on the three cog-
nitive domains between people taking antidepress-
ants and people who did not take antidepressants
Table 3. Characteristics of the psychotropic medication consumers and non-consumers
C ON S UM E R S
( N = 9 8 )
N O N -
C O N S UM E R S
( N = 1 0 8 )
M SD M SD t df p
............................................................................................................................................................................................................................................................................................................................
Age 84.9 5.3 85.5 4.5 −0.84 204 0.40
MMSE score 16.6 4.0 17.5 3.6 −1.61 204 0.11
Education 3.2 1.4 3.8 1.7 −2.83 204 0.005
Symptoms of depression 8.7 5.2 6.0 3.9 4.15 202 < 0.001
Symptoms of anxiety 16.2 5.6 13.9 4.1 3.21 200 0.001
Frequency (%) χ2 df p
Women 87 (89%) 93 (86%) 0.33 1 0.57
Ch-esterase inhibitor use 3 (3%) 5 (5%) 0.34 1 0.56
Cardiovascular disorders 87 (89%) 92 (85%) 0.58 1 0.45
Skin disorders 27 (28%) 21 (19%) 1.89 1 0.17
Tumors 17 (17%) 20 (19%) 0.05 1 0.83
Gastrointestinal disease 37 (38%) 35 (32%) 0.65 1 0.42
Locomotor disturbances 59 (60%) 54 (50%) 2.16 1 0.14
Neuro- and radiculopathy 17 (17%) 22 (20%) 0.31 1 0.58
Renal insufficiency 13 (13%) 16 (15%) 0.10 1 0.75
Pneumonic disease 26 (27%) 22 (20%) 1.09 1 0.30
Endocrine disorders 29 (30%) 26 (24%) 0.80 1 0.37
Ch= choline; MMSE=Mini-mental State Examination.
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Table 4. Means and standard deviations of the different neuropsychological test variables and the separate cognitive test variables and the 3 cognitive
domains.
C ON S PT
M ED S
( N = 9 8 )
N O N - C O N S
PT M ED S
( N = 1 0 8 )
C O N S
A N X / H Y / S E D
( N = 6 1 )
N O N - C O N S
A N X / H Y / S E D
( N = 1 4 5 )
C O N S
A N T I P S Y
( N = 4 4 )
N O N - C O N S
A N T I P S Y
( N = 1 6 2 )
C O N S
A N T I D E P
( N = 3 9 )
N O N - C O N S
A N T I D E P
( N = 1 6 7 )
T E S T S M ( SD ) M ( SD ) M ( SD ) M ( SD ) M ( SD ) M ( SD ) M ( SD ) M ( SD )
............................................................................................................................................................................................................................................................................................................................................................................................................................................................
DS forward 4.61 (1.6) 4.92 (1.9) 4.59 (1.7) 4.85 (1.9) 4.59 (1.6) 4.82 (1.9) 4.79 (1.6) 4.77 (1.9)
DS backward 3.46 (1.3) 3.95 (1.6) 3.56 (1.3) 3.79 (1.5) 3.14 (1.4) 3.88 (1.4) 3.62 (1.4) 3.74 (1.5)
Cat fluency 12.15 (5.7) 13.74 (6.5) 12.61 (6.1) 13.14 (6.2) 10.80 (4.7) 13.58 (6.4) 11.79 (4.6) 13.26 (6.5)
Face recog 5.68 (3.2) 5.08 (3.1) 5.67 (3.2) 5.23 (3.2) 5.02 (3.5) 5.45 (3.1) 5.16 (3.1) 5.41 (3.2)
Picture recog 12.29 (6.4) 11.58 (5.7) 12.23 (6.5) 11.78 (5.8) 10.57 (5.9) 12.27 (6.1) 13.00 (5.2) 11.66 (6.2)
8WT imm rec 15.65 (5.4) 17.10 (5.5) 15.92 (5.2) 16.62 (5.6) 13.95 (5.3) 17.08 (5.4) 16.67 (5.4) 16.35 (5.5)
8WT del rec 0.35 (0.9) 0.38 (0.9) 0.38 (0.9) 0.36 (0.9) 0.20 (0.6) 0.41 (1.0) 0.41 (1.1) 0.36 (0.9)
8WT recog 10.91 (2.3) 10.98 (2.2) 10.97 (2.3) 10.94 (2.2) 10.50 (2.2) 11.07 (2.2) 11.26 (1.9) 10.87 (2.3)
Domains§
EF/attention −0.13 (0.6) 0.16 (0.6) −0.09 (0.6) 0.07 (0.7) −0.33 (0.6) 0.11 (0.6) −0.05 (0.6) 0.02 (0.7)
Memory 0.04 (0.8) −0.03 (0.7) 0.04 (0.8) −0.01 (0.7) −0.16 (0.7) 0.05 (0.7) 0.08 (0.7) −0.03 (0.7)
Overall Cog −0.05 (0.6) 0.06 (0.5) −0.03 (0.6) 0.02 (0.5) −0.25 (0.5) 0.07 (0.5) 0.01 (0.6) −0.00 (0.6)
8WT=Eight words test; antidep= antidepressants; antipsy= antipsychotics; anx/hyp/sed= anxiolytics/hypnotics/sedatives; cat= category; cog= cognition; cons= consumers; del=delayed;
DS=digit span; EF= executive function; imm= immediate; M=mean; meds=medications; PT=psychotropic; rec= recall; recog= recognition; SD= standard deviation
§The cognitive domain scores are z-scores.
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(EF/attention: F(1,200)= 0.15, p= 0.695, ηp2 =
0.001; memory: F(1,200)= 0.42, p= 0.520, ηp2 =
0.002; overall cognition: F(1,200)= 0.02, p =
0.883, ηp2 = 0.000). The ANCOVA correcting
for symptoms of depression and anxiety showed
that people taking anxiolytics/hypnotic/sedatives
also did not differ from those not taking
anxiolytics/hypnotic/sedatives on the three cognitive
domains (EF/attention: F(1,198)= 1.47, p= 0.226,
ηp
2 = 0.007; memory: F(1,198)= 0.19, p= 0.663,
ηp
2 = 0.001; overall cognition: F(1,198)= 0.11,
p= 0.741, ηp2 = 0.001). An ANCOVA correcting
for MMSE score, education, symptoms of
depression and symptoms of anxiety revealed that
compared to people not taking antipsychotics,
people who were taking antipsychotics showed
worse performance on the EF/attention domain
(F(1,196)= 4.28, p= 0.040, ηp2 = 0.021), but
not on the memory domain and overall cognition
domain (F(1,196)= 0.09, p= 0.767, ηp2 = 0.000,
and F(1,196)= 2.09, p= 0.150, ηp2 = 0.011
respectively).
Number of classes of psychotropic medication
use
Spearman’s correlations between number of classes
of psychotropic agents and the EF/attention domain
were significant and negative (Spearman’s ρ =
0.22, p= 0.002), whereas the correlations between
number of classes and either memory or overall
cognition were not (Spearman’s ρ =−0.02,
p= 0.811, and Spearman’s ρ =−0.13, p= 0.065,
respectively).
Discussion
This is the first study to determine the relationship
between the use of different types of psychotropic use
(i.e. antidepressants, anxiolytics/hypnotic/sedatives,
and antipsychotics) and cognition in institution-
alized older adults with dementia. As in other
studies in a nursing home setting, psychotropic
medication was used by a large proportion of
participants (Ruths et al., 2001; Snowdon et al.,
2006; Tucker and Hosford, 2008). Almost half of
the current older residents were taking one or more
classes of psychotropic medication. Results show
that the use of psychotropicmedication, particularly
antipsychotics, and an increased number of
psychotropic agents used was inversely related
to executive/attentional functioning. In another
study including older people with dementia,
antipsychotic medication use was associated with
overall cognitive impairment, but that study did
not specify particular cognitive domains (Schneider
et al., 2006a).
Previous research suggests that older people
with worse executive/attentional functioning may
be at higher risk for certain adverse events. More
specifically, it has been shown that executive
function impairments in older people in assisted
living facilities require increased levels of care
(Burdick et al., 2005). Additionally, executive
function impairments in older people with dementia
are associated with falls (Sheridan and Hausdorff,
2007). Similarly, a direct relationship between
psychotropic medication use and falls was found
in older persons living in a nursing home (Cooper
et al., 2007). Consequently, the participants of the
present study taking antipsychotics are in need
of enhanced care, and may be at increased risk
for falls. Moreover, antipsychotic use in older
persons with dementia is associated with adverse
events including increased risk of cerebrovascular
events and increased risk of mortality (Valiyeva
et al., 2008). Clarifying the other risks of nursing
home residents with dementia using antipyschotic
medication should be the focus of future research
efforts.
The strengths of the present study include
specification of different classes of psychotropic
medication, the extensive neuropsychological test
battery and the nature of the studied population, i.e.
institutionalized older adults with dementia who are
difficult to include in lengthy neuropsychological
assessments (Teng and Manly, 2005). Short-
comings of the present study should be noted
as well. The first limitation is that baseline data
were used from an intervention study which
may have resulted in a reduced generalizibility of
the findings. On the other hand, willingness to
participate in a non-pharmacological intervention
study is not directly related to the present research
question. In addition, persons were recruited from
several different nursing homes and homes for
the elderly that were not part of the same care
organization, avoiding the influence of possible
treatment tendencies in certain homes. Secondly,
the present study did not account for duration
of psychotropic treatment. It has been shown in
older people that longer treatment duration of a
certain subtype of psychotropic medication can
have a different effect on cognition; antidepressants
can have a positive effect (Allard et al., 2003),
but non-benzodiazepines can have a negative
effect (Dealberto et al., 1997). The relationship
between treatment duration and cognition in older
persons with dementia remains unclear. Thirdly,
to determine the level of depressive symptoms,
the GDS was used which may not have been
appropriate in persons with moderately advanced
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dementia (Kørner et al., 2006). In future studies
it is recommended that an instrument specifically
designed for people with dementia be used, e.g.
the Cornell Scale for Depression in Dementia
(Alexopoulos et al., 1988). Another limitation of
the present study is the moderate Cronbach’s α of
the cognitive domains. Domains were formed to
avoid multiple testing and thus potential spurious
results. Ideally, Cronbach’s α would have been
higher; some cognitive tests, however, load on both
executive function and memory domains, but were
included in the domain that resulted in the highest
Cronbach’s α. Finally, the cross-sectional design of
the present study does not allow inferences about
the causation of the findings. More specifically, it
is known that a decline in executive function in
dementia may lead to symptoms such as impaired
judgment, disinhibition, and anxiety (Hannisdottir
andMorris, 2007; Tsoi et al., 2008). Onemay argue
that these symptoms may have led to the behavioral
disturbances, such as agitation and aggression,
for which antipsychotic medication was prescribed
(Alexopoulos et al., 2004).
Although effect sizes in the present study are
small, there appears to be an association between
antipsychotic medication use and impairment in
executive/attentional functioning in these older
institutionalized adults with dementia. Although
several studies have shown that a large proportion
of patients with dementia with accompanying
psychiatric symptoms are free of symptoms after
a cessation of antipsychotic medication (Reekum
et al., 2002; Ruths et al., 2008), in view of the
possible side effects of antipsychotic treatment
(Schneider et al., 2006b; Ballard et al., 2008), and
its association with decreased executive function,
frequent reconsideration of treatment with anti-
psychotics is recommended. This recommendation
is in line with the current recommendations of
international guidelines concerning antipsychotic
use in dementia (Alexepoulos et al., 2004; Rabins
et al., 2007). Longitudinal studies are needed to
further clarify the association between antipsychotic
medication use and executive/attentional function-
ing in institutionalized older people with dementia.
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